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ABSTRACT

The aim of this study was to utilize a continuous process for the production of Raloxifene
Hydrochloride (RX-HCl) loaded NLC formulations for extended drug release using hot-melt
extrusion technology coupled with probe sonication, and also to evaluate the in vitro characteristics
of the prepared NLCs by particle size, PDI, zeta potential, entrapment efficiency, drug loading,
and in vitro drug release profile. Preparation of the NLCs using HME technology involved two
main steps, first formation of a pre-emulsion after extrusion and then size reduction of the preemulsion using probe sonication to obtain the NLCs. Process parameters for the extrusion process
like feeding rates for the volumetric feeder and peristaltic pumps, were optimized. A screw speed
of 100 rpm and a barrel temperature of 85 °C, were used in the extrusion process. Characterization
of the NLCs involved assessment of particle size, PDI, zeta potential, entrapment efficiency, and
drug loading. NLCs prepared by HME technology generally showed a lower particle size
compared to those prepared by the conventional method. The prepared NLCs had high entrapment
efficiency values (>90 %). In vitro drug release was evaluated using dialysis bag diffusion
technique and USP apparatus 1 (rotating basket). The pure drug showed a faster rate of drug release
compared to the NLCs which showed an extended release of the drug. NLCs prepared by HME
technology generally showed a higher rate of drug release compared to those prepared by the
conventional method. Particle size of the prepared NLCs remained relatively stable over the
storage period and all PDI and zeta potential values were ≤ 0.523 and in the range of -15 to -30
mV, respectively, indicating good physical stability of the formulations. In summary, HME
ii

technology and probe sonication were successfully used to prepare RX-HCl loaded NLC
formulations as a continuous manufacturing process with shorter processing times as compared to
the conventional method, which makes this technique a more industry friendly method.
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CHAPTER I: INTRODUCTION

Nanostructured lipid carriers (NLCs) are a second generation of lipid nanoparticles which offer
some advantages over the Solid Lipid Nanoparticles (SLNs) [1]. Advantages offered by the NLCs
over the SLNs include higher drug incorporation capacity, improved drug release properties, easier
manufacturing process, and less amount of stabilizers required compared to the SLNs [2]. NLCs
are produced using a combination of solid lipids and liquid lipids which are organized in
nanocompartments inside the solid lipid matrix [3]. The Active Pharmaceutical Ingredient (API)
in the NLC is incorporated in the liquid lipid and is encapsulated by the solid lipid [3]. This
configuration gives the drug some degree of mobility and offers stability to some extent [3]. NLCs
are safe and compatible colloidal drug carriers which are able to provide controlled delivery of the
API and have various drug delivery applications via the oral, dermal, pulmonary, and ocular routes
[4].
Various methods have been used to produce NLCs and most of these methods have been reported
in literature and they include high-pressure homogenization, micro-emulsification, solvent
displacement, supercritical fluid technology, high-shear homogenization, and ultrasonication [4].
However, these methods have some disadvantages that include multistep processing, poor energy
efficiency, potential for dilution of particle dispersion, and frequent failures due to batch-to-batch
variations [3]. These disadvantages make the conventional methods used for NLC production less
industry friendly.
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Hot-melt extrusion (HME) processing was established in the early 1930s and during that time it
rapidly became the most widely applied processing technology in the plastic, rubber, and food
industries [5]. HME is a continuous pharmaceutical process that involves pumping polymeric
materials with a rotating screw at temperatures above their glass transition temperature (Tg) and
sometimes above the melting temperature (Tm) to achieve molecular level mixing of the active
compounds and thermoplastic binders, polymers, or other excipients [5]. This molecular level
mixing converts the components into an amorphous product with a uniform shape and density,
thereby increasing the dissolution profile of the poorly water soluble drug [5]. HME has gained
increased interest in the pharmaceutical industry due to advantages that include: HME provides
faster and more efficient time to achieve the final product, environmental advantages due to the
elimination of solvent use, increased efficiency of drug delivery to the patient, formulations with
high drug loading can be manufactured by HME with the desired release profile, good content
uniformity can be achieved for very low drug loading due to intimate mixing of components, HME
allows conversion of API to amorphous form which can result in enhanced bioavailability, HME
is a scalable continuous process and product quality can be monitored online, inline, or offline,
and desired dosage forms can be easily manufactured by HME process [5], [6]. HME technology
gained a lot of attention and importance in the recent decade after the US Food and Drug
Administration encouraged the use of continuous manufacturing processes [3].
RX-HCl is a selective estrogen receptor modulator (SERM) with a chemical structure as depicted
in Figure 1. RX-HCl acts as an estrogen agonist on bone and on the liver and therefore increases
bone mineral density and decreases fracture incidence [7]. It is used in the prevention of
osteoporosis and prevention of invasive breast cancer in postmenopausal women, although, its
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therapeutic efficacy is limited by its low solubility in physiological pH conditions and also
undergoes extensive first pass metabolism [7].
In the current study, a continuous production process will be used for the production of RX-HCl
loaded NLCs for extended drug release using hot-melt extrusion technology coupled with probe
sonication. Physicochemical characteristics of the prepared NLC formulations will be evaluated
by particle size, polydispersity index (PDI), zeta potential, entrapment efficiency, drug loading,
and in vitro drug release. Process parameters for the extrusion process like feeding rates for the
volumetric feeder and peristaltic pumps, were optimized. The continuous production process used
in this study will overcome most of the limitations presented by the conventional methods.

Figure 1. Chemical Structure of RX-HCl
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CHAPTER II: MATERIALS AND METHODS

2.1. MATERIALS
RX-HCl, liquid lipids (capmul MCM C8, castor oil, and labrafil M 1944 CS), and surfactants
(polysorbate 80, polysorbate 20, and cremophor EL) were purchased from Fisher Scientific
(Hanover Park, IL USA). Solid lipids, glyceryl monostearate, compritol 888ATO, precirol ATO5,
and dynasan 118 were gifted from Gattefossé (Paramus, NJ USA). All other chemicals and
solvents (methanol, acetonitrile) used in the study were of HPLC grade and de-ionized water was
used throughout the study.

2.2. METHODS
2.2.1. Selection of Solid Lipids, Liquid Lipids, and Surfactants
Solid lipids were selected by checking the solubility of RX-HCl in melted solid lipid by means of
visual observation with the naked eyes under normal light. This was further characterized with
HPLC analysis. Solid lipids, glyceryl monostearate, compritol 888ATO, precirol ATO5, and
dynasan 118 were screened for their potential to solubilize RX-HCl. Liquid lipids, capmul MCM
C8, castor Oil, and labrafil M 1944 CS, were screened for their potential to solubilize RX-HCl.
RX-HCl compatibility with various 1 % surfactant solutions, polysorbate 80, polysorbate 20, and
cremophor EL was assessed. After the screening studies, two solid lipids, two liquid lipids, and
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two surfactants were selected for further studies. The solid and liquid lipids used in this study were
reported to be safe, biocompatible, and biodegradable. All experiments were conducted in
triplicate.
2.2.2. Preparation of NLC Formulations
Two batches consisting of 24 blank NLC formulations in each batch, were prepared by the
conventional probe sonication method. The 1st batch consisted of only one primary surfactant
while the 2nd batch consisted of a primary surfactant and a co-surfactant. Composition of the blank
NLC formulations is as shown in Table 1. All prepared formulations were stored at 25 °C/ 60 %
RH to check for stability. Based on the stability results, formulations F4-2 and F4-3 from the 2nd
batch were selected for the preparation of RX-HCl loaded NLC formulations using conventional
probe sonication and HME methods. The concentration (% w/v) of the solid and liquid lipids,
surfactants, and co-surfactant (Poloxamer 188) in the drug-loaded NLC formulations, is as shown
in Table 1 and RX-HCl concentration was kept constant at 1.2 % w/v in all the formulations.
Preparation of RX-HCL loaded NLCs using HME technology involved two main steps. The first
step involved the formation of a pre-emulsion by extruding a combination of solid lipid, RX-HCl,
liquid lipid, and the aqueous phase through the HME barrel, and the second step involved size
reduction of the pre-emulsion utilizing probe sonication to obtain the NLC formulation. Extrusion
was carried out on an 11-mm co-rotating twin screw extruder (11-mm Process 11™, Thermo
Fisher Scientific, Karlsruhe, Germany). Schematic representation of preparation of the NLC
formulations using HME and probe sonication is as shown in Figure 2. The solid lipid was passed
through a sieve (Standard Mesh No. 16) for size reduction and to improve its flowability. RX-HCl
5

was uniformly mixed with the solid lipid, and introduced in the barrel using a volumetric feeder.
Liquid lipid and aqueous phase (solution of surfactants and water) were heated to 85 °C and then
respectively, injected in zone 2 and zone 4 of the barrel using peristaltic pumps. A screw speed of
100 rpm, barrel temperature of 85 °C, and sonication time of 10 minutes, were used in this study.
Volumetric feeder and peristaltic pump feeding rates were optimized in this study. Figure 3 shows
the screw configuration [3], with a barrel temperature of 85 °C that was used for the extrusion
process. The pre-emulsion obtained was subjected to probe sonication (SONICS Vibracell™,
Sonics and Material, Inc., Newton, CT) with an amplitude of 40 %, to obtain the RX-HCl loaded
NLCs.

6

Table 1. Composition of blank NLC formulations

2.2.3. Characterization of NLC Formulations
Particle size (z-average diameter) and polydispersity index (PDI) were measured by dynamic light
scattering technique using Malvern Zetasizer Nano ZS (Malvern Instruments, UK) at 25 °C [8].
Zeta potential was also measured using the same instrument. Prior to measurements, the
formulations were suitably diluted with distilled water (100x dilution factor) and all measurements
were carried out at a scattering angle of 90° at 25 °C. Percent entrapment efficiency and drug
7

loading of the prepared NLC formulations were determined [9]. Entrapment efficiency was
determined by calculating the entrapped drug after removal of the unentrapped drug using Amicon
filters (100 kDa MWCO) centrifuged at 13,000 rpm for 15 minutes at 20 °C. The filtrate was
diluted appropriately with methanol and analyzed using a suitable HPLC method as described in
the analytical method section . The following formulas were used to calculate percent entrapment
efficiency and drug loading [10];
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑅𝑋−𝐻𝐶𝑙 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑁𝐿𝐶𝑠

% Entrapment efficiency = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑅𝑋−𝐻𝐶𝑙 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 ∗ 100

𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑅𝑋−𝐻𝐶𝑙 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑁𝐿𝐶𝑠

% Drug loading = 𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑅𝑋−𝐻𝐶𝑙 𝑎𝑛𝑑 𝑙𝑖𝑝𝑖𝑑𝑠 𝑎𝑑𝑑𝑒𝑑 𝑡𝑜 𝑡ℎ𝑒 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛 ∗ 100

2.2.4. HPLC Analysis Method for Raloxifene Hydrochloride
RX-HCl was analyzed using HPLC (Waters Corporation) equipped with a UV-vis detector
operating at 288 nm. Samples were chromatographed on a stainless steel RP-C18 column with
dimensions of 250 x 4.6 mm, packed with 5 µm particles. The mobile phase consisted of a mixture
of acetonitrile (33 % v/v) and monobasic potassium phosphate buffer (67 % v/v). A flow rate of 1
mL/min and an injection volume of 10 µL were used for analysis [11].
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Figure 2. Schematic representation of preparation of RX-HCl loaded NLCs using HME
technology coupled with probe sonication [3]

2.2.5. In vitro Drug Release Studies
In vitro release of RX-HCl from NLCs was evaluated using dialysis bag diffusion technique with
some modifications [12]. The receptor compartment (drug release media) consisted of 500 mL pH
6.8 phosphate buffer containing 0.5 % v/v polysorbate 80 to maintain sink conditions. The dialysis
bags were soaked in the release media overnight prior to the experiment. RX-HCl loaded NLC
formulation (equivalent to 18 mg of RX-HCl) was placed in the dialysis bags (12-14 kDa MWCO)
and then the bags were tightly sealed at both ends to avoid any leakages. The dialysis bags were
immersed in the receptor compartment placed in USP apparatus 1 vessels and maintained at 37 ±
1 °C and 100 rpm. At predetermined time points, aliquots of 1 mL were withdrawn from the release
media and filtered through 0.45 µm filter. The concentration of RX-HCl in the filtrate was suitably
analyzed using the HPLC method as described in the analytical method section. Equal amounts (1
mL) of fresh release media were added to the receptor compartment immediately after withdrawal
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to maintain a constant release media volume. All experiments were conducted in triplicate and the
average values were taken. At the end of the experiment, percent drug release was calculated to
determine RX-HCl release mechanism from the NLC formulations.

Figure 3. Screw configuration used for the extrusion process

2.2.6. Stability Study
The physicochemical stability of the prepared NLC formulations was assessed based on particle
size, polydispersity index, zeta potential, percent entrapment efficiency, and percent drug loading.
These parameters were assessed at the beginning and end of the stability period. The NLC
formulations were stored at 25 °C/ 60 % RH and 40 °C/ 75 % RH for a period of one month.
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CHAPTER III: RESULTS AND DISCUSSION

3.1. SELECTION OF SOLID LIPIDS, LIQUID LIPIDS, AND SURFACTANTS
The first step in the selection of lipids for the preparation of NLC formulations, is the assessment
of solubility of drug in the solid and liquid lipids. This is because solubility of the drug in the lipids
is one of the most important factors for determining entrapment efficiency of the drug in NLC
formulations [13]. Four solid lipids, three liquid lipids, and three surfactants with different
physicochemical properties were assessed for RX-HCl solubility and compatibility. With the aid
of visual observation with naked eyes under normal light, solubility of RX-HCl in the lipids was
based on the amount of precipitated drug at the bottom of the scintillation vials at the end of the
solubility studies, and this amount of precipitated drug was inversely proportional to the solubility
of RX-HCl in the lipids. Solubilization capacity of the lipids for RX-HCl was in the following
order; glyceryl monostearate > compritol 888ATO > precirol ATO5 > dynasan 118 for solid lipids,
and capmul MCM C8 > castor oil > labrafil M 1944 CS for the liquid lipids. Based on the results,
solid lipids, glyceryl monostearate and compritol 888ATO, and liquid lipids, capmul MCM C8
and castor oil, were selected for further studies since they had a lower amount of precipitated drug
compared to the other lipids, and hence had a higher solubilization capacity for RX-HCl.
Surfactants, polysorbate 80 and cremophor EL were reported to be compatible with RX-HCl [14],
[15].
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3.2. PREPARATION OF NLC FORMULATIONS
HME technology is a continuous process of pumping raw materials at high temperatures and
pressures resulting in a product of uniform shape and density [16], [17], [18]. Preparation of RXHCL loaded NLCs involved the formation of a pre-emulsion by extruding a combination of solid
lipid, RX-HCl, liquid lipid, and the aqueous phase through the HME barrel, and finally size
reduction of the pre-emulsion utilizing probe sonication to obtain NLC formulations. The
extruder’s screw consisted of a conveying system and mixing zones which helped in transport and
efficient mixing, a die at the end of the barrel, and downstream equipment that was used to collect
the pre-emulsion for further processing [3]. The screw configuration is a very important aspect of
HME and has a significant contribution to the characteristics of the final product [19]–[21]. The
screw configuration as shown in Figure 3, had two mixing zones. The first mixing zone served the
purpose of mixing the melted solid lipid and RX-HCl with the liquid lipid and the second mixing
zone served the purpose of efficiently mixing the oil and aqueous phase to form a pre-emulsion
that was collected in a beaker at the end of the barrel for further processing. It took about 2 hours
to prepare 10 mL of the NLC formulation using the conventional method, while with the HME
technique, 400 mL of the NLC formulation was produced in less than one hour. This makes the
HME technique used in this study a faster and industry friendly method for the preparation of NLC
formulations. Production of the NLC formulations by the conventional method is a batch process
which is time consuming and may result in variability of end-product quality attributes. The HME
technique used in this study is a continuous manufacturing process and is able to overcome
challenges in variability of end-product quality attributes.
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3.3. CHARACTERIZATION OF THE NLC FORMULATIONS
As part of the preliminary studies, two batches consisting of 48 blank NLC formulations, were
prepared by the conventional probe sonication method. Composition of the blank NLC
formulations is as shown in Table 1. Assessment of formulation variables of the blank NLC
formulations from the 1st and 2nd batches was based on particle size, PDI, and zeta potential
measurements after a 14-day storage stability period. Particle size, PDI, and zeta potential are key
factors for evaluating the stability of colloidal dispersions [22], [23]. Selection of formulations for
further studies was based on stability results and the physical properties (e.g. gelling) of the
formulations. Based on the stability results as shown in Figure 4, the 2nd batch showed a relatively
more stable particle size compared to the 1st batch. On day 14, particle size was within a range of
242.9 ± 6.76 to 721.2 ± 188.20 for the 1st batch and 192.9 ± 3.28 to 416.9 ± 7.90 for the 2nd batch,
and thus F4-2 and F4-3 from the 2nd batch were selected for further studies for preparation of RXHCl loaded NLC formulations using the conventional probe sonication and HME methods. This
could be explained by the tendency of the primary surfactant/co-surfactant combination of the 2nd
batch to stabilize the system [24]. RX-HCl loaded NLC formulations prepared by the HME
technique generally showed a lower particle size compared to the NLCs prepared by the
conventional method. On Day 0, particle size of the NLCs prepared by HME was 229.6 ± 6.35 and
199.5 ± 1.23 for F4-2 and F4-3 respectively compared to 327.4 ± 9.79 and 284.2 ± 45.08 for F4-2
and F4-3 respectively for NLCs prepared by the conventional method. The reduced particle size
can be explained by the additional shearing effect of the screws in the HME extrusion process that
could cause a reduction in particle size of the extruded pre-emulsion material.

13

3.4. ENTRAPMENT EFFICIENCY AND DRUG LOADING
Percent entrapment efficiency and drug loading results for F4-2 and F4-3 RX-HCl loaded NLC
formulations are as shown in Figure 5. The high entrapment efficiency values (> 90 %) can be
explained by the high solubilization capacity of the lipids and a relatively high surfactant
concentration that leads to increased solubility of the drug in the lipid [25]. F4-3 NLC formulations
generally had relatively higher entrapment efficiency values (97.65 % ± 0.029 for the conventional
method) compared to F4-2 (96.10 % ± 0.069 for the conventional method) and this can be
explained by the effect of increasing the liquid lipid concentration from 1.5 % w/v in F4-2 to 2 %
w/v in F4-3. High proportion of liquid lipid may help increase drug solubility in lipid matrix which
leads to high entrapment efficiency [26]. NLC formulations prepared by HME showed a relatively
higher entrapment efficiency and this could be explained by the high shear generated by the screws
inside the barrel which may cause more interaction of drug, lipids, and surfactant resulting in a
homogeneous emulsion and an increase in entrapment efficiency [16].
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Figure 4. Particle size, PDI, and zeta potential for the blank NLC formulations
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Figure 5. Percent entrapment efficiency and drug loading for the prepared NLC formulations

3.5. IN VITRO DRUG RELEASE STUDIES
RX-HCl is very slightly soluble in water and so, 0.5% v/v Polysorbate 80 was added to the release
media in order to increase its saturation solubility, as well as to maintain the sink condition. In
vitro release of RX-HCl from the F4-2 and F4-3 optimized formulations prepared by the
conventional method and HME technology, was compared to the release of the pure drug over a
period of 30 hours. The release profile of the prepared NLC formulations is as shown in Figure 6.
The amount of RX-HCl released from the NLC formulations was determined by an in vitro dialysis
bag that retained the NLC particles, whereas the drug released from the NLCs diffused through
the dialysis membrane into the release media. It can be observed that the pure drug showed a faster
rate of drug release in the first 8 hours compared to the RX-HCl loaded NLC formulations which
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showed a sustained release of RX-HCl, and from the 8th to the 30th hour, the pure drug showed a
much slower rate of drug release compared to the drug loaded NLCs. This indicates that lipid
carriers play a predominant role in sustaining the drug release. The sustained release of the drug
from the NLC formulations may be explained by the increased diffusional distance and hindering
effects of the surrounding solid lipid shell. It has also been reported that a reduced particle size (in
the nm range) as seen in the NLC formulations, provides sustained drug delivery [4]. Based on
statistical analysis, there was a significant difference in dissolution profile between the drug loaded
NLCs and the pure drug as follows: t = -1.092, p < 0.05 and t = -0.959, p < 0.05 for F4-2 and F43 formulations prepared by the conventional method respectively, and t = -0.983, p < 0.05 and t =
-0.655, p < 0.05 for F4-2 and F4-3 formulations prepared by HME technology respectively. F4-3
NLC formulations generally showed a higher dissolution rate than the F4-2 NLC formulations and
this may be explained by the decrease of the solid lipid amount and increase in liquid lipid amount
in F4-3 NLC formulations that could cause a reduction of formulation viscosity and hence lead to
an increase in dissolution rate. NLC formulations prepared by HME also showed a higher
dissolution rate than those prepared by the conventional method. Based on statistical analysis,
there was a significant difference (t = -2.398, p < 0.05 and t = -4.309, p < 0.05 for F4-2 and F4-3
respectively) in dissolution profile between formulations prepared by the conventional method and
those prepared by HME technology. This effect could have resulted from the further reduction of
particle size and increase in surface area of the NLC formulations prepared by the HME method.
According to Nernst-Noyes-Whitney equation, which describes the dissolution rate of drug in a
diffusion-controlled process, an increase in the surface area could result in an increase in the
dissolution rate [27]–[30].
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Figure 6. In vitro drug release profile of the prepared RX-HCl loaded NLC formulations

3.6. STABILITY STUDIES
Stability results are as shown in Table 2. Particle size, PDI, and zeta potential are key factors for
evaluating the stability of colloidal dispersions [22], [23]. Based on statistical analysis, there was
a significant difference in particle size between Day 0 and Day 30 for formulations prepared by
the conventional method and stored at 25 °C/ 60 % RH (t = -20.111, p < 0.05) and 40 °C/ 75 %
RH (t = -1.129, p < 0.05); and also a significant difference for formulations prepared by HME
technology and stored at 25 °C/ 60 % RH (t = -4.901, p < 0.05) and 40 °C/ 75 % RH (t = -118.5,
p < 0.05). Despite these differences, the particle size of the NLC formulations were kept within a
18

desirable submicron range (less than 300 nm) except for F4-3 prepared by the conventional method
that had a particle size of 483.9 ± 8.85 on day 30. The higher particle size of F4-3 could be
explained by the low negative zeta potential value (-17.9 ± 2.63) on day 30 that could cause
flocculation of the nanoparticles. There was a significant difference (t = 13.931, p < 0.05) in
particle size on day 0 between NLC formulations prepared by the conventional method and HME
technology. The low particle size of the NLCs prepared by HME could be explained by the
additional shearing effect of the screws in the HME extrusion process that could cause a reduction
in particle size. A low PDI value indicates a narrow size distribution, whereas a high PDI value
indicates a broad size distribution [31]. Usually a PDI value below 0.5 is acceptable [31]. All PDI
values were within an acceptable range (≤ 0.523), and thus the change in PDI was not considered
to be significant in the present study. The amount of charge on the particle surface is one of the
important characteristics giving information on the tendency of nanoparticles to agglomerate and
on their long-term stability [4], [32]. A zeta potential greater than -60 mV is known to require for
excellent physical stability of nanoparticles, whereas greater than -30 mV it indicates good
electrostatic stabilization and good physical stability [4], [33]. All zeta potential values were within
an acceptable range of -15 to -30 mV, and thus the change in zeta potential was not considered to
be significant in the present study.
In the present study, all PDI and zeta potential values were kept within an acceptable range, and
this indicates good physical stability of the prepared NLC formulations.
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Table 2. Particle size, PDI, and zeta potential of the drug loaded NLCs

20

CHAPTER 4: CONCLUSION

HME technology coupled with probe sonication was successfully utilized to prepare RX-HCl
loaded NLC formulations as a continuous manufacturing process with shorter processing times as
compared to the conventional method. HME coupled with probe sonication is a continuous
manufacturing process that is able to overcome challenges in variability of end-product quality
attributes that are common with the conventional batch process. Results from this study suggest
an efficient method that can be used to prepare RX-HCl loaded NLC formulations with extended
drug release and good physical stability, and hence could provide a better regimen for the
prevention and treatment of postmenopausal osteoporosis
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